Our Pricing

Is Wegovy As Effective As Mounjaro? Compare Both Here

Many UK patients ask is Wegovy as effective as Mounjaro when choosing a weight loss treatment. Clinical trial evidence shows both medications produce significant results, but tirzepatide (Mounjaro) demonstrates superior weight loss outcomes compared to semaglutide (Wegovy) in head-to-head studies. At Cured Pharmacy, our UK-registered prescribers assess your individual circumstances to recommend the most appropriate treatment, with transparent pricing and discreet delivery across the UK.

Clinical Trial Evidence: Mounjaro vs Wegovy Effectiveness

The SURPASS-2 trial directly compared tirzepatide and semaglutide in adults with type 2 diabetes, providing robust evidence on relative effectiveness [1]. Participants receiving the highest tirzepatide dose (15mg) achieved an average weight reduction of 11.2kg over 40 weeks, compared to 5.7kg with semaglutide 1mg — nearly double the weight loss [1].

In obesity-specific trials, the SURMOUNT-1 study demonstrated that tirzepatide produced up to 22.5% total body weight reduction at 72 weeks, whilst the STEP-1 trial showed semaglutide 2.4mg (Wegovy) achieved 14.9% weight loss over 68 weeks [2][3]. Both medications significantly outperform placebo, but tirzepatide consistently delivers greater absolute weight reduction across dosing ranges.

These differences reflect tirzepatide's dual mechanism as both a GIP and GLP-1 receptor agonist, compared to semaglutide's single GLP-1 pathway [1]. The additional GIP activation appears to enhance metabolic effects and appetite suppression, translating to measurably greater clinical outcomes in controlled studies.

How Each Medication Works in Your Body

Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a natural hormone released after eating [3]. This medication slows gastric emptying, increases feelings of fullness, and reduces appetite signals to the brain. Semaglutide has been used in the UK since 2018 for diabetes management (as Ozempic) and received MHRA licensing for weight management in 2022.

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK [1]. Beyond the GLP-1 effects seen with semaglutide, tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action enhances insulin secretion, improves fat metabolism, and produces more pronounced appetite suppression than single-pathway treatments.

Both medications require once-weekly subcutaneous injection and follow gradual dose escalation protocols to minimise gastrointestinal side effects. Your UK prescriber will determine the appropriate starting dose based on your medical history, current medications, and weight management goals.

What to Expect During Treatment

Most patients begin noticing reduced appetite within the first week of treatment with either medication. Measurable weight loss typically becomes apparent after 4-8 weeks, with continued gradual reduction over subsequent months as doses are titrated upward [2][3]. Clinical trials show maximum weight loss generally occurs between 60-72 weeks of continuous treatment, though individual responses vary considerably.

Both Wegovy and Mounjaro are intended as long-term treatments combined with reduced-calorie diet and increased physical activity. Discontinuing treatment often results in weight regain, which is why UK prescribers emphasise sustainable lifestyle modifications alongside pharmacotherapy. Your treatment plan will include regular reviews to assess progress, manage side effects, and adjust dosing as needed.

Is Wegovy as Effective as Mounjaro for Different Patient Groups?

Clinical effectiveness varies based on individual factors including baseline BMI, metabolic health, and adherence to lifestyle modifications. In SURMOUNT-1, participants with higher baseline BMI experienced greater absolute weight loss with tirzepatide, though percentage reductions remained consistent across BMI categories [2]. Similar patterns emerged in STEP trials for semaglutide, suggesting both medications work across diverse patient populations.

Patients with type 2 diabetes may experience additional benefits from either medication beyond weight loss, including improved glycaemic control and reduced cardiovascular risk markers [1][4]. The SURPASS trials demonstrated tirzepatide's superior HbA1c reduction compared to semaglutide in diabetic populations, which may influence prescriber recommendations for patients managing both conditions.

Age, gender, and ethnicity appear to have minimal impact on relative effectiveness, though clinical trials have predominantly enrolled white participants aged 40-65 [2][3]. UK prescribers consider your complete medical profile when recommending treatment, as certain conditions or medications may make one option more suitable than the other despite overall efficacy differences.

Contraindications and Precautions

Neither medication is suitable for patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3][4]. Both carry warnings about potential thyroid C-cell tumours based on rodent studies, though human relevance remains uncertain. Your UK prescriber will screen for these conditions during your clinical assessment.

Patients with severe gastrointestinal disease, pancreatitis history, or diabetic retinopathy require careful evaluation before starting either treatment. Pregnancy and breastfeeding are contraindications for both Wegovy and Mounjaro, and effective contraception is recommended during treatment due to limited safety data in these populations.

Side Effects: What UK Patients Experience

Gastrointestinal side effects are the most commonly reported adverse events with both medications, affecting 30-50% of patients in clinical trials [2][3]. Nausea, diarrhoea, constipation, and vomiting typically occur during dose escalation and often diminish as your body adjusts. These effects are generally mild to moderate and rarely lead to treatment discontinuation when doses are increased gradually.

Tirzepatide appears to cause slightly higher rates of gastrointestinal side effects compared to semaglutide in head-to-head studies, though the difference is modest [1]. This may reflect the stronger appetite suppression and gastric effects from dual receptor activation. Taking the injection on the same day each week, staying well-hydrated, and eating smaller meals can help minimise discomfort.

Serious adverse events are rare with both medications but include potential pancreatitis, gallbladder problems, and hypoglycaemia (particularly in patients taking other diabetes medications) [3][4]. Superintendent pharmacist Tarun Kumar emphasises the importance of reporting persistent abdominal pain, visual changes, or signs of allergic reaction to your prescriber immediately. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey.

Cost Considerations: Wegovy vs Mounjaro Pricing at Cured Pharmacy

At Cured Pharmacy, Mounjaro starts from £135.00 for UK patients following clinical assessment by our registered prescribers. This transparent upfront pricing includes your medication, consultation, and discreet delivery across the UK. We guarantee the lowest prices in the UK market, with no hidden fees or surprise charges at checkout.

Wegovy is available from £135.00, making it a lower-cost option whilst still delivering clinically significant weight loss outcomes. The price difference reflects manufacturing costs and market positioning rather than quality — both are genuine UK-licensed medications dispensed by our GPhC-registered pharmacy (registration number 9012511). Your prescriber will discuss both options during your consultation, ensuring you understand the clinical and financial considerations.

Long-term treatment costs vary depending on your prescribed maintenance dose, which may increase during titration. Most patients reach their optimal dose within 16-20 weeks and continue at that level for sustained weight management. Our team provides clear pricing information for each dose level before you commit to treatment, allowing you to make informed decisions about your weight loss journey.

NHS vs Private Prescription Options

The NHS currently provides limited access to GLP-1 medications for weight management through specialist weight management services, with strict eligibility criteria including BMI thresholds and comorbidity requirements [5]. Waiting times for NHS weight management programmes often exceed 12-18 months in many UK regions, prompting many patients to seek private treatment for faster access.

Private prescription through Cured Pharmacy offers same-day clinical assessment, with medication typically dispatched within 24-48 hours of approval. Our UK-registered prescribers conduct thorough consultations to ensure treatment safety and suitability, providing the same clinical rigour as NHS services with considerably reduced waiting times and greater treatment flexibility.

Making Your Decision: Which Treatment Should You Choose?

If maximum weight loss is your primary goal and budget allows, clinical evidence suggests Mounjaro delivers superior outcomes across most patient populations [1][2]. The approximately 7-8 percentage point difference in average weight reduction may translate to substantial absolute differences depending on your starting weight — potentially 5-10kg additional loss over 12-18 months of treatment.

Wegovy remains an excellent choice for patients seeking clinically significant weight loss at a lower price point, particularly those who may not tolerate the stronger effects of tirzepatide. Many UK prescribers recommend starting with semaglutide and considering tirzepatide if results plateau or prove insufficient after 6-9 months of optimised treatment.

Your individual response cannot be predicted with certainty regardless of average trial outcomes. Factors including medication adherence, dietary changes, physical activity levels, and metabolic differences all influence real-world effectiveness. Our prescribers at Cured Pharmacy assess your complete medical profile, treatment goals, and personal circumstances to recommend the most appropriate option, with flexibility to adjust your treatment plan based on your progress and tolerability.

Starting Your Weight Loss Journey with Cured Pharmacy

Beginning treatment takes under three minutes with our streamlined online consultation process. You'll answer questions about your medical history, current medications, weight loss goals, and any previous weight management attempts. Our UK-registered prescribers review every consultation individually — this is not an automated process — ensuring treatment safety and appropriateness.

Once approved, your medication is dispensed from our GPhC-registered pharmacy and delivered in 100% discreet packaging with no external branding. We provide comprehensive patient information leaflets, injection technique guidance, and ongoing clinical support throughout your treatment. You can contact our pharmacy team on (+44) 116 4646009 with any questions or concerns about your medication.

Scientific References

1. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg solution for injection in pre-filled pen (tirzepatide). MHRA. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. Retrieved from https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and the weight loss outcomes cited reflect average results from clinical trials and may not be representative of all patients.